Ozempic and Wegovy are making so much money for Novo Nordisk A/S that their cumulative sales will soon surpass the ...

Key Takeaways Novo Nordisk CEO Lars Fruergaard Jorgensen will testify Tuesday before a Senate panel looking into the drug ...

In a high-profile showdown Tuesday with Sen. Bernie Sanders’ Senate health committee, Novo Nordisk CEO Lars Fruergaard ...

Novo Nordisk CEO Lars Fruergaard Jørgensen faces a Senate hearing led by Bernie Sanders over the high cost of Ozempic and ...

Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jorgensen will use a familiar argument to defend the US prices of ...

Ozempic and Wegovy are making so much money for Novo Nordisk A/S that their cumulative sales will soon surpass the ...

As the Senate Committee on Health, Education, Labor and Pensions (HELP) gears up for a hearing tomorrow titled “Why Is Novo ...

In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D ...

CEO Lars Fruergaard Jørgensen will face questioning from the Senate Committee on Health, Education, Labor, and Pensions about the cost of its GLP-1 drugs, Wegovy and Ozempic.  Health Care Reporter ...

O faturamento da farmacêutica dinamarquesa Novo Nordisk com o Ozempic e o Wegovy é tanto que as vendas acumuladas logo ...

Ozempic maker Novo Nordisk’s highly anticipated new obesity pill, Amycretin, shows the potential for much greater and faster ...

Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more ...